TD Asset Management Inc. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 11.7% in the third quarter, selling over 181,000 shares. Despite this, other institutional investors increased their positions. The biopharmaceutical company recently announced positive Phase III results for izalontamab brengitecan, increased its quarterly dividend to $0.63, and reported a revenue beat but an EPS miss for Q4.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
TD Asset Management Inc Trims Stake in Bristol Myers Squibb Company $BMY
TD Asset Management Inc. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 11.7% in the third quarter, selling over 181,000 shares. Despite this, other institutional investors increased their positions. The biopharmaceutical company recently announced positive Phase III results for izalontamab brengitecan, increased its quarterly dividend to $0.63, and reported a revenue beat but an EPS miss for Q4.